Atara Biotherapeutics, Inc. (NASDAQ:ATRA) marched up 39.96% compared to a 52-week low price of $27.85. The shares were last seen trading -4.11% lower, taking the closing price at $38.98 on 3/14/2019. At a recent session, the prices were hovering between $38.91 and $41.14. This company shares are 21.86% off its target price of $47.5 and the current market capitalization stands at $1.81B. The recent change has given its price a 5.85% lead over SMA 50 and -28.41% deficit over its 52-week high. The stock witnessed -0.74% declines, -7.98% declines and -5.04% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ATRA’s volatility during a week at 4.42% and during a month it has been found around 5.13%.

Atara Biotherapeutics, Inc. (ATRA) Top Holders

Institutional investors currently hold around $1.96 billion or 0% in ATRA stock. Look at its top three institutional owners: Baupost Group Llc/Ma owns $254.25 million in Atara Biotherapeutics, Inc., which represents roughly 14.05% of the company’s market cap and approximately 12.97% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 5,274,169 shares of the stock are valued at $214.4 million. The third largest holder is Redmile Group, Llc, which currently holds $179.45 million worth of this stock and that ownership represents nearly 9.91% of its market capitalization.

Atara Biotherapeutics, Inc. 13F Filings

At the end of December reporting period, 60 institutional holders increased their position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by some 3,754,935 shares, 55 decreased positions by 1,723,046 and 20 held positions by 42,775,189. That puts total institutional holdings at 48,253,170 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 840,708 shares while 14 institutional investors sold out their entire positions totaling 544,355 shares.

Atara Biotherapeutics, Inc. (ATRA) Analyst Guide

Several analysts have released their opinion on Atara Biotherapeutics, Inc. (NASDAQ:ATRA), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.12 average brokerage recommendation [T1].